Taiwanese IVD (In-Vitro Diagnostic) manufacturer General Biologicals Corporation (GBC) unveiled two CellBio circulating tumor cell (CTC) cancer detection products at the American Association for Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo, being held July 23-27 in Anaheim, California.
GBC’s two CTC detection systems are used for early detection, treatment validation and therapy monitoring with rapid, accessible and affordable diagnostic solutions. The CellBio platform, which uses GBC proprietary iFiltration technology, provides positive control, and is designed to ensure the filtration efficiency is accurate. The technology was patented and won the 2022 Taiwan National Innovation Award.
